Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is a clinical stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases such as Geographic Atrophy and Stargardt disease type 1. The company's lead product candidate, tinlarebant, has received multiple designations from both the FDA and Japanese regulatory agencies and is expected to achieve FDA approval in 1Q27. The company also has a successful and ongoing Phase 3 trial for tinlarebant, with positive interim data expected in 2H26. Belite Bio's strong financials and potential for multiple billions in revenue from tinlarebant make it a solid investment choice with a current buy rating and a $200 price target.

Bears say

Belite Bio is a biopharmaceutical company with high potential in developing innovative therapies for degenerative retinal diseases and metabolic diseases. However, the company is currently in the clinical stage and has no product revenue, and its stock performance is heavily reliant on the success of its lead product candidate, tinlarebant, which is facing a highly competitive landscape in the market. Additionally, the company may face challenges in securing sufficient funding for its ongoing and future clinical trials and potential commercialization of its products, which may impact its long-term growth prospects.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.